EORTC abstracts selected at ESMO 2020 Virtual Congress
17 Sep 2020
5 EORTC abstracts were selected for ESMO 2020 that will take place virtually from 19 until 21 September 2020.
On-Demand Mini Oral Sessions
Mini Oral Session-Sarcoma
A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint – an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis
- Presentation Number:1628MO
- Date: 18 September 2020
- Speaker: Georgios Kantidakis (Brussels, Belgium)
First-line chemotherapy (CT) in advanced well-differentiated/ dedifferentiated liposarcoma (WD/DD LPS): an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
- Presentation Number: 1629MO
- Date: 18 September 2020
- Speaker: Silvia Stacchiotti
Mini Oral Session – Non-metastatic NSCLC and other thoracic malignancies
LATE BREAKING ABSTRACT: REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
- Presentation Number: LBA85
- Date: 18 September 2020
- Speaker: Benjamin Besse (Villejuif, CEDEX, France)
Proffered Paper Session
Proffered Paper Session: Melanoma and Other Skin Cancers
LATE BREAKING ABSTRACT: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase 3 trial
- Presentation Number: LBA46
- Date: 19 September 2020
- Lecture Time: 17:16 – 17:28
- Speaker: Alexander M. Eggermont (Utrecht, Netherlands)
Poster display session
Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: a multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
- Presentation Number: 1919P
- Date: 17 September 2020
- Speaker: Kate Newbold (Sutton, United Kingdom)
For more information, visit ESMO 2020 online programme.
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023